ASSESSMENT OF GENOTOXICITY OF VINCRISTINE,
VINBLASTINE AND VINORELBINE IN HUMAN CULTURED
LYMPHOCYTES: A COMPARATIVE STUDY
Mhaidat NM, Alzoubi KH, Khabour OF, Alawneh KZ, Raffee LA,
Alsatari ES, Hussein EI, Bani-Hani KE
*Corresponding Author: Nizar M. Mhaidat, Ph.D., Department of Clinical Pharmacy, Faculty of Pharmacy,
Jordan University of Science and Technology, Amman-Ramtha Hwy, Irbid 22110, Jordan. Tel: +962-
2-720-100. Fax: +962-2-720-1075. E-mail: nizarm@just.edu.jo
page: 13
|
|
REFERENCES
1. Facchini PJ, De Luca V. Opium poppy and Madagascar
periwinkle: Model non-model systems to
investigate alkaloid biosynthesis in plants. Plant
J. 2008; 54(4): 763-784.
2. Moudi MR, Go R, Yien CY, Nazre M. Vinca alkaloids.
Int J Prev Med. 2013; 4(11): 1231-1235.
3. Duffin J. Poisoning the spindle: Serendipity
and discovery of the anti-tumor properties of
the Vinca alkaloids. Pharm Hist. 2002; 44(2?):
64-76.
4. Ribatti D, Guidolin D, Conconi MT, Nico B,
Baiguera S, Parnigotto PP, et al. Vinblastine
inhibits the angiogenic response induced by
adrenomedullin in vitro and in vivo. Oncogene.
2003; 22(41): 6458-6461.
5. Toussaint C, Izzo J, Spielmann M, Merle S, May-
Levin F, Armand JP, et al. Phase I/II trial of continuous
infusion vinorelbine for advanced breast
cancer. J Clin Oncol. 1994; 12(10): 2102-2112.
6. Freyer G, Delozier T, Lichinister M, Gedouin D,
Bougnoux P, His P, et al. Phase II study of oral
vinorelbine in first-line advanced breast cancer
chemotherapy. J Clin Oncol. 2003; 21(1): 35-40.
7. Rusthoven J, Bramwell V, Stephenson B. Use of
granulocyte colony-stimulating factor (G-CSF)
in patients receiving myelosuppressive chemotherapy
for the treatment of cancer. Provincial
Systemic Treatment Disease Site Group. Cancer
Prev Control. 1998; 2(4): 179-190.
8. Hirano M, Okamoto M, Maruyama F, Ezaki K,
Shimizu K, Ino T, et al. Alternating non-crossresistant
chemotherapy for non-Hodgkin’s lymphoma
of inter-mediate-grade and high-grade
malignancy. A pilot study. Cancer. 1992; 69(3):
772-777.
9. Coderch C, Morreale A, Gago F. Tubulin-based
structure-affinity relationships for antimitotic
Vinca alkaloids. Anticancer Agents Med Chem.
2012; 12(3): 219-225.
10. Jiang W, Lu Y, Chen Z, Chen S, Zhang M, Jin
L, et al. Studying the genotoxicity of vincristine
on human lymphocytes using comet assay, micronucleus
assay and TCR gene mutation test in
vitro. Toxicology. 2008; 252(1-3): 113-117.
11. Choudhury RC, Palo AK, Padhy A. Cytogenetic
consequences of vinblastine treatment in mouse
bone marrow. Chemotherapy. 2004; 50(4): 171-177.
12. Morales-Ramirez P, Vallarino-Kelly T, Cruz-
Vallejo V. Kinetics of micronucleus induction
and cytotoxicity caused by distinct antineoplastics
and alkylating agents in vivo. Toxicol Lett.
2014; 224(3): 319-325.
13. Morales-Ramirez P, Vallarino-Kelly T, Cruz-
Vallejo V. Kinetics of micronucleated polychromatic
erythrocyte (MN-PCE) induction in vivo by
aneuploidogens. Mutat Res. 2004; 565(1): 79-87.
14. Yamada T, Odawara K, Kaneko H. Concurrent
detection of gene mutations and chromosome
aberrations induced by five chemicals in a CHL/
IU cell line incorporating a gpt shuttle vector.
Mutat Res. 2000; 471(1-2): 29-36.
15. Arni P, Hertner T. Chromosomal aberrations in
vitro induced by aneugens. Mutat Res. 1997;
379(1): 83-93.
16. Gonzalez-Cid M, Larripa I, Slavutsky I. Vinorelbine:
Cell cycle kinetics and differential sensitivity
of human lymphocyte subpopulations.
Toxicol Lett. 1997; 93(2-3): 171-176.
17. Tiburi M, Reguly ML, Schwartsmann G, Cunha
KS, Lehmann M, Rodrigues de Andrade HH.
Comparative genotoxic effect of vincristine,
vinblastine, and vinorelbine in somatic cells
of Drosophila melanogaster. Mutat Res. 2002;
519(1-2): 141-149.
18. Gundy S, Baki M, Bodrogi I. Vinblastine, cisplatin
and bleomycin (VPB) adjuvant therapy does not
induce dose-dependent damage in human chromosomes.
Neoplasma. 1989; 36(4): 457-464.
19. Morgan WF, Crossen PE. A comparison of induced
sister chromatid exchange levels in Chinese
hamster ovary cells and cultured human lymphocytes.
Environ Mutagen. 1982; 4(1): 65-71.
20. Gonzalez-Cid M, Cuello MT, Larripa I. Mitotic
arrest and anaphase aberrations induced by
vinorelbine in hamster cells in vitro. Anticancer
Drugs. 1997; 8(5): 529-532.
21. Alzoubi K, Khabour O, Khader M, Mhaidat N,
Al-Azzam S. Evaluation of vitamin B12 effects
on DNA damage induced by paclitaxel. Drug
Chem Toxicol. 2014; 37(3): 276-280.
22. Alzoubi K, Khabour O, Hussain N, Al-Azzam S,
Mhaidat M. Evaluation of vitamin B12 effects
on DNA damage induced by pioglitazone. Mutat
Res. 2012; 748(1-2): 48-51.
23. Alsatari ES, Azab M, Khabour OF, Alzoubi KH,
Sadiq MF. Assessment of DNA damage using
chromosomal aberrations assay in lymphocytes
of waterpipe smokers. Int J Occup Med Environ
Health. 2012; 25(3): 218-224.
24. Khabour OF, Alsatari ES, Azab M, Alzoubi KH,
Sadiq MF. Assessment of genotoxicity of waterpipe
and cigarette smoking in lymphocytes
using the sister-chromatid exchange assay: A
comparative study. Environ Mol Mutagen. 2011;
52(3): 224-228.
25. Alzoubi KH, Khabour OF, Jaber AG, Al-Azzam
SI, Mhaidat NM, Masadeh MM. Tempol prevents
geno-toxicity induced by vorinostat: role
of oxidative DNA damage. Cytotechnology.
2014; 66(3): 449-455.
26. Khabour OF, Alzoubi KH, Mfady DS, Alasseiri
M, Hasheesh TF. Tempol protects human lymphocytes
from genotoxicity induced by cisplatin.
Int J Clin Exp Med. 2014; 7(4): 982-988.
27. Al-Sweedan SA, Khabour O, Isam R. Genotoxicity
assessment in patients with thalassemia
minor. Mutat Res. 2012; 744(2): 167-171.
28. Kaya FF, Topaktas M. Genotoxic effects of potassium
bromate on human peripheral lymphocytes
in vitro. Mutat Res .2007; 626(1-2): 48-52.
29. M’Bemba-Meka P, Lemieux N, Chakrabarti SK.
Role of oxidative stress and intracellular calcium
in nickel carbonate hydroxide-induced sisterchromatid
exchange, and alterations in replication
index and mitotic index in cultured human
peripheral blood lymphocytes. Arch Toxicol.
2007; 81(2): 89-99.
30. Rooney DE, Ed. Human Cytogenetics. A Practical
Approach, 3rd ed., Vol. 2: Malignancy and
Acquired Abnormalities. Oxford, UK: Oxford
University Press, 2001.
31. Khabour OF, Saleh N, Alzoubi KH, Hisaindee
S, Al-Fyad D, Al-Kaabi L, et al. Genotoxicity
of structurally related copper and zinc containing
Schiff base complexes. Drug Chem Toxicol.
2013; 36(4): 435-442.
32. Ivett JL, Tice RR. Average generation time: A
new method of analysis and quantitation of cellular
proliferation kinetics. Environ Mutagen.
1982; 4: 358-370.
33. Tsai KL, Chiu TH, Tsai MH, Chen HY, Ou HC.
Vinorelbine-induced oxidative injury in human
endothelial cells mediated by AMPK/PKC/
NADPH/NF-kappaB pathways. Cell Biochem
Biophys. 2012; 62(3): 467-479.
34. Zhao J, Li H, Zhai Q, Qiu Y, Niu Y, Dai Y, et al.
[Endonuclease modified comet assay for oxidative
DNA damage induced by detection of
genetic toxicants]. Zhonghua Yu Fang Yi Xue
Za Zhi. 2014; 48(3): 208-212.
35. Madhu P, Reddy KP, Reddy PS. Melatonin reduces
oxidative stress and restores mitochondrial
function in the liver of rats exposed to chemotherapeutics.
J Exp Zool A Ecol Genet Physiol.
2015; 323(5): 301-308.
36. Lee-Chen SF, Chen CL, Ho LY, Hsu PC, Chang
JT, Sun CM, et al. Role of oxidative DNA damage
in hydroxychavicol-induced genotoxicity.
Mutagenesis. 1996; 11(5): 519-523.
37. Ogura H, Takeuchi T, Morimoto K. A comparison
of the 8-hydroxydeoxyguanosine, chromosome
aberrations and micronucleus techniques
for the assessment of the genotoxicity of mercury
compounds in human blood lymphocytes. Mutat
Res. 1996; 340(2-3): 175-182.
38. Tari C, Fournier N, Briand C, Ducet G, Crevat
A. Action of vinca alkaloides on calcium
movements through mitochondrial membrane.
Pharmacol Res Commun. 1986; 18(6): 519-528.
39. Sanchez P, Llorente MT, Castano A. Flow cytometric
detection of micronuclei and cell cycle
alterations in fish-derived cells after exposure
to three model genotoxic agents: Mitomycin C,
vincristine sulfate and benzo(a) pyrene. Mutat
Res. 2000; 465(1-2): 113-122.
40. Le Fevre AC, Boitier E, Marchandeau JP, Sarasin
A, Thybaud V. Characterization of DNA reactive
and non-DNA reactive anticancer drugs by gene
expression profiling. Mutat Res. 2007; 619(1-2):
16-29.
41. Geriyol P, Basavanneppa HP, Dhananjaya BL.
Protecting effect of caffeine against vinblastine
(an anticancer drug) induced genotoxicity in
mice. Drug Chem Toxicol. 2015; 38(2): 188-195.
42. Wang YJ, Zhang LS. [Evaluation of the genotoxicity
of vincristine and colchicine using mouse
lymphoma tk mutation assay]. Wei Sheng Yan
Jiu. 2006; 35(2): 179-181.
43. Choudhury RC, Das B, Misra S, Jagdale MB.
Cytogenetic toxicity of vincristine. J Environ
Pathol Toxicol Oncol. 2000; 19(4): 347-355.
44. Xing SG, Shi X, Wu ZL, Chen JK, Wallace W,
Whong WZ, et al. Transplacental genotoxicity of
triethyl-enemelamine, benzene, and vinblastine
in mice. Teratog Carcinog Mutagen. 1992; 12(5):
223-230.
45. Novichkova EA, Onishchenko GE, Shtil AA.
Microtubule depolymerization by vincristine
causes cell death after transition from C mitosis
to interphase. Dokl Biol Sci. 2003; 393: 575-578.
46. Horton JK, Houghton PJ, Houghton JA. Relationships
between tumor responsiveness, vincristine
pharmacokinetics and arrest of mitosis in
human tumor xenografts. Biochem Pharmacol.
1988; 37(20): 3995-4000.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
